Evidence map›Paper›PMID 27941773›Full record

Trial reportBone marrow transplantation2017

Haploidentical transplantation for pediatric patients with acquired severe aplastic anemia.

L P Xu, X H Zhang, F R Wang, X D Mo, T T Han, W Han, Y H Chen, Y Y Zhang, J Z Wang, C H Yan and 3 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 3 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 84 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Haploidentical HSCT in the Treatment of Pediatric Hematological Disorders.International journal of molecular sciences · 2024
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

L P XuHematology Department, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
X H ZhangHematology Department, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
F R WangHematology Department, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
X D MoHematology Department, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
T T HanHematology Department, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
W HanHematology Department, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Y H ChenHematology Department, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Y Y ZhangHematology Department, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
J Z WangHematology Department, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
C H YanHematology Department, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Y Q SunHematology Department, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
S N ZuoHematology Department, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
X J HuangHematology Department, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Peking University · CNPeking University People's Hospital · CNCenter for Life Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Techniques for haploidentical hematopoietic stem cell transplantation (haplo-HSCT) to treat severe aplastic anemia (SAA) have recently improved, but no protocol has been evaluated in a large number of pediatric patients. Fifty-two children with SAA received haplo-HSCT in our center. The treatment protocol used G-CSF-primed bone marrow with G-CSF-mobilized PBSCs without in vitro T-cell depletion. The conditioning regimen included busulfan/cyclophosphamide and antithymocyte globulin. Fifty-one patients achieved primary engraftment; one child died of regimen-related toxicity on the day +1. Secondary graft failure occurred in three patients. The cumulative incidences of aGVHD grade II-IV and grade III-IV were 39.2±0.5 and 13.7±0.2%, respectively. The cumulative incidence of cGVHD was 34.2±0.5%. The 3-year overall and failure-free survival rates were 84.5±5.0 and 82.7±5.2%, respectively, with a median follow-up time of 744.5 days (100-3294) for surviving patients. The Eastern Cooperative Oncology Group score was the only predictor of overall and failure-free survival rates. Clinical outcomes were similar between the upfront and salvage group. This result suggests that both newly diagnosed and refractory pediatric SAA patients benefit from haplo-HSCT, especially when patients are in good general condition. Therefore, haplo-HSCT might be an alternative therapy for pediatric SAA patients without HLA-matched sibling donors.

Indexed as

Hematopoietic Stem Cell MobilizationPeripheral Blood Stem Cell TransplantationTissue DonorsTransplantation ConditioningAdolescentAllograftsAnemia, AplasticBusulfanChildChild, PreschoolCyclophosphamideDisease-Free SurvivalFemaleGranulocyte Colony-Stimulating FactorHumansInfantBusulfanCyclophosphamideGranulocyte Colony-Stimulating Factor

Identifiers

PMID27941773
OpenAlexW2565516774

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.